MoneyWorks4Me

Bajaj Healthcare gets DCGI approval to manufacture, market Cenobamate API, Tablets

13 Aug 2026 Evaluate

Bajaj Healthcare has received approval from the Drugs Controller General of India (DCGI) under the Central Drugs Standard Control Organization (CDSCO) to manufacture and market Cenobamate API and Cenobamate Tablets in strengths of 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg.

With this regulatory approval, Bajaj Healthcare becomes the first company to launch Cenobamate in India, marking a significant milestone in the company's journey towards bringing advanced therapies to patients and further strengthening its presence in the Central Nervous System (CNS) segment.

The approval follows the recommendation of the Subject Expert Committee (SEC) for grant of approval for the manufacture and marketing of Cenobamate Tablets, as previously communicated by the Company through its press release dated 26th June 2026.

Cenobamate is a next-generation antiseizure medication indicated for the treatment of partial-onset seizures in adults. Clinical studies have demonstrated significant seizure reduction and high seizure-freedom rates in patients with inadequately controlled epilepsy, supporting its potential as an important treatment option in the evolving landscape of epilepsy care.

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.


Bajaj Healthcare Share Price

322.20 -0.90 (-0.28%)
18-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1876.40
Dr. Reddys Labs. 1180.50
Cipla 1431.85
Lupin 2225.00
Zydus Lifesciences 1117.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: